These include prognostic gene signatures for oestrogen receptor (ER)-positive and HER2-negative breast cancer patients, the assessment of HER2/neu status by FISH or IHC, OncoType Dx tests and MammaPrint assessments of 70 genes associated with tumour recurrence. Here, ERBB2 is linked to neoplasm.